A new consortium of 27 international partners from academia, industry, and small and medium enterprises, aims to tackle the unmet challenge of discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative and metabolic diseases.
Discovering and developing
innovative and effective brain transport mechanisms
New BBB models
establishing and characterising BBB models with good predictability in health and disease
identifying translational read-outs closer to the pathogenesis of neurodegeneration and mimicking altered BBB under disease conditions
Principal project objectives
- Discovery and development of innovative and efficacious brain transport mechanisms
- Establishment and characterisation of BBB models with good predictability in health and disease
- Identification of translational readouts closer to the pathogenesis of neurodegeneration and mimicking altered BBB under disease conditions
- In-depth understanding of the biology of the BBB and characterization of various pathophysiological mechanisms across the BBB
Efficient drug delivery across
the blood-brain barrier.
Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain
“This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 807015. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.“
The project is being run by
The organizations included
in the research programme.